IFNA2, interferon alpha 2, 3440

N. diseases: 355; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients. 31329012 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE The enhanced function of pDC and IFN-α2 might involve triggering the immune response from IT to hepatitis active phase in HBV infection. 29271379 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and 48th week after withdrawal, in order to provide guidance on the antiviral treatment of HBeAg-positive CHB patients. 29055925 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 AlteredExpression disease BEFREE IFN-α2 elevation was associated with ALT level in patients with chronic HBV infection. 30058578 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy. 29314573 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 GeneticVariation disease BEFREE IFNA2 p.Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor. 28958921 2017
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. 28229987 2017
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 AlteredExpression disease BEFREE The reduction in HBV DNA levels by TRK-560 treatment was significantly higher than that by PEG-IFN-α2a treatment both <i>in vitro</i> and <i>in vivo</i> (<i>P</i> = 0.004 and <i>P</i> = 0.046, respectively), and intracellular HBV covalently closed circular DNA (cccDNA) reduction by TRK-560 treatment was also significantly higher than that by PEG-IFN-α2a treatment <i>in vivo</i> (<i>P</i> = 0.0495). cDNA microarrays and ELISA for CXCL10 production revealed significant differences between TRK-560 and PEG-IFN-α2a in the induction potency of interferon-stimulated genes. 28373196 2017
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE It may be concluded that the ability of the peg IFN-α-2a to clear and suppress cccDNA and HBV DNA was superior compared with that of conventional IFN-α-2a. 26382279 2016
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 GeneticVariation disease BEFREE Herein, we report the results obtained by the addition of peg-interferon α-2a to a long-lasting nucleos(t)ide analogue therapy in a HBeAg negative, genotype D patient with steadily HBV-DNA negative/HBsAg positive values. 25024631 2014
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. 23639931 2013
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. 22267464 2012
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 GeneticVariation disease LHGDN The promoter of the IFN-alpha-2 gene was investigated for mutations in 344 hepatitis B virus (HBV)-infected Vietnamese patients and 293 uninfected Vietnamese. 16920161 2006
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 GeneticVariation disease BEFREE The promoter of the IFN-alpha-2 gene was investigated for mutations in 344 hepatitis B virus (HBV)-infected Vietnamese patients and 293 uninfected Vietnamese. 16920161 2006
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. 16557544 2006
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection. 16611278 2006
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE When the combination of large dosage interferon-alpha 2b and lamivudine therapy in children was compared at the end of therapy and 6 months after therapy, normalization of alanine aminotransferase and the clearances of hepatitis B e antigen and hepatitis B surface antigen in both groups were directly proportional to the duration of treatment. 11642634 2001
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Therapeutic disease CTD_human Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation. 11112032 2000
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Therapeutic disease CTD_human Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. 10836394 2000
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 GeneticVariation disease BEFREE Twenty-nine hepatitis B surface antigen carriers with normal liver enzymes and with serum hepatitis B virus DNA were randomized into two groups: Group I, 14 patients treated with 9 megaunits of interferon alpha-2a thrice weekly for six months, and Group II, 15 control patients. 9298736 1997
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Therapeutic disease CTD_human Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. 9339942 1997
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Interferon-alpha 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. 8947886 1996
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Recombinant interferon-alpha 2a (IFN-alpha 2a) in a total dose of 702 MU was given to 31 patients: nine with wild-type hepatitis B virus (HBV) and hepatitis B e antigen (HBeAg) (A); four with HBeAg and a mixed infection with wild-type HB and precore mutants (B); 11 with antibody to HBeAg (HBeAb) and a mixed infection (C); and seven with HBeAb and precore mutants alone (D). 8745316 1995
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE These findings suggest that, in children as well as in adults, recombinant interferon-alpha 2a favors the clearance of hepatitis B virus replication, enhancing the host antiviral immunoresponse. 8045488 1994
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 AlteredExpression disease BEFREE All patients had hepatitis B virus DNA and increased levels of aminotransferases in serum for at least 1 yr. Twelve children received 10 MU of interferon-alpha 2b/m2 body surface area three times a week (group I); 12 children received 5 MU/m2 under the same conditions (group II); and 12 children served as controls (group III). 2050319 1991